These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
591 related articles for article (PubMed ID: 29159742)
21. Pleuropulmonary Recurrence Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Appendiceal Pseudomyxoma Peritonei. Beane JD; Wilson GC; Sutton JM; Shuai Y; Ramalingam L; Jones HL; Pingpank JF; Holtzman MP; Zureikat AJ; Ahrendt SA; Zeh HJ; Bartlett DL; Choudry HA Ann Surg Oncol; 2019 May; 26(5):1429-1436. PubMed ID: 30623341 [TBL] [Abstract][Full Text] [Related]
22. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239 [TBL] [Abstract][Full Text] [Related]
23. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Chua TC; Moran BJ; Sugarbaker PH; Levine EA; Glehen O; Gilly FN; Baratti D; Deraco M; Elias D; Sardi A; Liauw W; Yan TD; Barrios P; Gómez Portilla A; de Hingh IH; Ceelen WP; Pelz JO; Piso P; González-Moreno S; Van Der Speeten K; Morris DL J Clin Oncol; 2012 Jul; 30(20):2449-56. PubMed ID: 22614976 [TBL] [Abstract][Full Text] [Related]
24. [Efficacy of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei]. Lei ZY; Ding BH; Wu QY; Luo JL; Li Z; Wang T; Wang YS; Chen YX; Huang LF; He JF; Yang XS; Guan TP; Ruan Q; Wang JH; Tang HS; Wang J; Cui SZ Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Dec; 26(12):1179-1186. PubMed ID: 38110280 [No Abstract] [Full Text] [Related]
25. The 7th Edition of the AJCC Staging Classification Correlates with Biologic Behavior of Mucinous Appendiceal Tumor with Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC). Milovanov V; Sardi A; Studeman K; Nieroda C; Sittig M; Gushchin V Ann Surg Oncol; 2016 Jun; 23(6):1928-33. PubMed ID: 26714951 [TBL] [Abstract][Full Text] [Related]
26. Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei Arising from Urachus. Liu Y; Ishibashi H; Hirano M; Takeshita K; Mizumoto A; Ichinose M; Nishino E; Kashu I; Yamamoto Y; Sugarbaker PH; Yonemura Y Ann Surg Oncol; 2015 Aug; 22(8):2799-805. PubMed ID: 25572681 [TBL] [Abstract][Full Text] [Related]
27. Long term survival analysis after hyperthermic intraperitoneal chemotherapy with oxaliplatin as a treatment for appendiceal peritoneal carcinomatosis. Masckauchan D; Trabulsi N; Dubé P; Aubé-Lecompte ME; Cloutier AS; Mitchell A; Sideris L Surg Oncol; 2019 Mar; 28():69-75. PubMed ID: 30851915 [TBL] [Abstract][Full Text] [Related]
28. Surveillance of Low-Grade Appendiceal Mucinous Neoplasms With Peritoneal Metastases After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Are 5 Years Enough? A Multisite Experience. Solomon D; Bekhor E; Leigh N; Maniar YM; Totin L; Hofstedt M; Aycart SN; Carr J; Ballentine S; Magge DR; Golas BJ; Pai RK; Polydorides AD; Bartlett DL; Labow DM; Choudry HA; Sarpel U Ann Surg Oncol; 2020 Jan; 27(1):147-153. PubMed ID: 31385130 [TBL] [Abstract][Full Text] [Related]
29. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery. Kusamura S; Barretta F; Yonemura Y; Sugarbaker PH; Moran BJ; Levine EA; Goere D; Baratti D; Nizri E; Morris DL; Glehen O; Sardi A; Barrios P; Quénet F; Villeneuve L; Gómez-Portilla A; de Hingh I; Ceelen W; Pelz JOW; Piso P; González-Moreno S; Van Der Speeten K; Deraco M; JAMA Surg; 2021 Mar; 156(3):e206363. PubMed ID: 33502455 [TBL] [Abstract][Full Text] [Related]
30. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976 [TBL] [Abstract][Full Text] [Related]
31. A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process. Carr NJ; Cecil TD; Mohamed F; Sobin LH; Sugarbaker PH; González-Moreno S; Taflampas P; Chapman S; Moran BJ; Am J Surg Pathol; 2016 Jan; 40(1):14-26. PubMed ID: 26492181 [TBL] [Abstract][Full Text] [Related]
32. Which classification system defines best prognosis of mucinous neoplasms of the appendix with peritoneal dissemination: TNM vs PSOGI? Martín-Román L; Lozano P; Gómez Y; Fernández-Aceñero MJ; Vasquez W; Palencia N; González-Bayón L J Clin Pathol; 2023 Apr; 76(4):266-273. PubMed ID: 34725195 [TBL] [Abstract][Full Text] [Related]
33. Long-term survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Waikato, Aotearoa New Zealand: a 12-year experience. Qin RX; Lim JH; Ly J; Fischer J; Smith N; Karalus M; Wu L; van Dalen R; Lolohea S ANZ J Surg; 2024 Apr; 94(4):621-627. PubMed ID: 37994292 [TBL] [Abstract][Full Text] [Related]
34. Early Postoperative Intraperitoneal Chemotherapy for Low-Grade Appendiceal Mucinous Neoplasms with Pseudomyxoma Peritonei: Is it Beneficial? Huang Y; Alzahrani NA; Liauw W; Traiki TB; Morris DL Ann Surg Oncol; 2017 Jan; 24(1):176-183. PubMed ID: 27718032 [TBL] [Abstract][Full Text] [Related]
35. Overall Survival is More Closely Associated with Peritoneal than Primary Appendiceal Pathological Grade in Pseudomyxoma Peritonei with Discordant Pathology. Memon AA; Godbole C; Cecil T; Dayal S; Moran B; Tzivanakis A; Mohamed F; Carr NJ Ann Surg Oncol; 2022 Apr; 29(4):2607-2613. PubMed ID: 34731401 [TBL] [Abstract][Full Text] [Related]
36. Analysis of causes and prognostic impact of tube occlusion during hyperthermic intraperitoneal chemotherapy for appendiceal pseudomyxoma peritonei. Liu Q; Jiao J; Li C; Chen Y; Wang B; Shi J; Yu G World J Surg Oncol; 2024 May; 22(1):134. PubMed ID: 38769546 [TBL] [Abstract][Full Text] [Related]
37. Outcomes of cytoreductive surgery and HIPEC for pseudomyxoma peritonei of appendiceal origin from two Indian centers: A preliminary five-year experience. Bhatt A; Sheshadri D; Chandan G; Ramaswamy V; Pandey J; Bhorkar N; Agrawal D; Mehta S J BUON; 2017; 22(1):251-257. PubMed ID: 28365962 [TBL] [Abstract][Full Text] [Related]
38. Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA). Milovanov V; Sardi A; Ledakis P; Aydin N; Nieroda C; Sittig M; Nunez M; Gushchin V Eur J Surg Oncol; 2015 May; 41(5):707-12. PubMed ID: 25633641 [TBL] [Abstract][Full Text] [Related]
39. Association between preoperative appendiceal histology grade and Pseudomyxoma peritonei grade offers a solution to avoid right hemicolectomy during cytoreductive surgery and HIPEC. Ghandour R; Bardier A; Wagner M; Malgras B; Kaci R; Doat S; Pocard M Surg Oncol; 2024 Oct; 56():102123. PubMed ID: 39163796 [TBL] [Abstract][Full Text] [Related]
40. Correlation between PSOGI pathological classification and survival outcomes of patients with pseudomyxoma peritonei treated using cytoreductive surgery and HIPEC: national referral centre experience and literature review. Martín-Román L; Hannan E; Faraz Khan M; Müller AS; Shields C; Aird J; Moran B; Mulsow J Pleura Peritoneum; 2023 Jun; 8(2):65-74. PubMed ID: 37304162 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]